The MEVION S250 is designed to provide proton beams physicians can use to treat tumors, lesions or any other condition where radiotherapy is indicated.
“Completing this very important milestone is a testament to the maturity of the Mevion organization and its ability to manufacture, install and support a safe and effective product,” said Joseph Jachinowski, CEO of Mevion Medical Systems, in the release. “We are pleased to receive this clearance from the FDA and now look forward to providing our customers and their patients access to this revolutionary device.”
The first installation of the MEVION S250 will soon be completed at the Kling Center for Proton Therapy at Barnes Jewish Hospital at Washington University in St. Louis, Mo.
Mevion Medical Systems is headquartered in Littleton, Mass.
Related Articles on FDA Clearances:
Melicor Medical Receives FDA Approval for Laparoscopic Lens Internal Cleaning System
Hansen Medical Receives FDA 510(k) Clearance for Peripheral Vascular Interventions System
Medicrea Receives FDA Clearance for the LigaPASS Spinal Fixation System
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
